Jim Cramer Calls Becton Dickinson a Buy, Citing Strong Fundamentals

CNBC host and former hedge fund manager Jim Cramer recommended purchasing shares of medical technology giant Becton, Dickinson and Co. on his June 6, 2026, broadcast of Mad Money. Cramer advised investors to initiate a position and then wait, highlighting the company's defensive characteristics and strong fundamentals. The commentary comes as BDX shares have declined approximately 7% year-to-date, underperforming the broader health care sector.

Context — why this matters now

Cramer's endorsement arrives during a period of heightened market uncertainty, with the S&P 500 Volatility Index (VIX) recently trading near 18.5. The medical device sector has faced pressure from concerns over potential changes to elective procedure volumes and hospital capital spending. Becton Dickinson, a S&P 500 component, represents a bellwether for hospital supply chains and global health infrastructure. Cramer’s public stock picks often trigger short-term retail trading activity, though his longer-term performance track record is mixed.

The last significant Cramer call on BDX occurred in late 2025, when he expressed caution on supply chain headwinds. The current shift to a buy recommendation signals a change in sentiment towards the company's near-term prospects. The catalyst for the call appears to be BDX's recent reaffirmation of its full-year 2026 financial guidance during its last earnings presentation.

Data — what the numbers show

Becton Dickinson's stock closed at $248.75 on June 6, giving the company a market capitalization of approximately $72 billion. The stock trades at a forward price-to-earnings ratio of 18.5x, a premium to its five-year average of 16.8x but a discount to the broader health care equipment sector average of 21x. Year-to-date, BDX is down 7.2%, significantly underperforming the Health Care Select Sector SPDR Fund (XLV), which is up 3.5% over the same period.

The company reported Q2 2026 revenue of $5.2 billion, a 3.4% increase year-over-year on a currency-neutral basis. Adjusted earnings per share for the quarter were $3.12, beating consensus estimates by $0.07. BDX's dividend yield stands at 1.6%, below the sector average but supported by 52 consecutive years of dividend increases.

Analysis — what it means for markets / sectors / tickers

Cramer's recommendation could provide a near-term sentiment boost for the entire medical device sector, potentially benefiting peers like Abbott Laboratories (ABT) and Medtronic (MDT). These companies face similar macroeconomic pressures but offer comparable defensive characteristics. Institutional ownership of BDX stands near 85%, indicating that major moves would require broad fundamental reassessment rather than retail flow alone.

The primary counter-argument to the buy thesis centers on valuation. Despite its recent underperformance, BDX still trades at a premium to its own historical valuation on several metrics. A sustained slowdown in hospital procedure volumes could pressure the company's high-margin interventional segment, which accounts for nearly 40% of total revenue. Hedge fund positioning data shows a slight increase in short interest in BDX over the past month, rising from 1.2% to 1.8% of float.

Outlook — what to watch next

Investors should monitor BDX's Q3 2026 earnings release, scheduled for August 6, 2026, for confirmation of guidance and procedure volume trends. Key technical levels include near-term resistance at the 50-day moving average of $255 and support at the recent low of $240. The next major catalyst for the sector will be the July ISM Manufacturing PMI report on August 1, which provides insight into hospital capital equipment purchasing trends.

Any commentary from management on the upcoming FDA review of the company's novel drug-eluting stent platform will be critical. A positive regulatory decision could provide a significant catalyst for the interventional segment. Monitor the 10-year Treasury yield, as rising rates typically pressure high multiple defensive stocks like BDX.

Frequently Asked Questions

What is Becton Dickinson's main business?

Becton Dickinson is a global medical technology company focused on improving drug delivery, enhancing the diagnosis of infectious diseases, and advancing drug discovery. The company operates three segments: Medical, which produces needles and syringes; Life Sciences, focused on diagnostic systems; and Interventional, which makes surgical and vascular access products. BDX employs over 70,000 people worldwide and operates in nearly every country.

How accurate are Jim Cramer's stock picks?

The accuracy of Jim Cramer's stock recommendations varies significantly across studies and time periods. An analysis by CNBC in 2023 found that his charitable trust's stock picks outperformed the S&P 500 over a 10-year horizon. However, academic studies have shown mixed results, with some indicating that his buy recommendations underperform the market on a risk-adjusted basis over shorter time frames following the broadcast.

Is Becton Dickinson a good dividend stock?

Becton Dickinson is a considered a reliable dividend stock, having increased its dividend for 52 consecutive years, earning it the designation of a Dividend Aristocrat. The current yield of 1.6% is modest but supplemented by consistent growth. The company's payout ratio is approximately 45% of earnings, providing a comfortable margin of safety for continued dividend growth alongside reinvestment in the business.

Bottom Line

Cramer's buy call highlights BDX's defensive appeal during market uncertainty but requires sustained fundamental improvement.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.